WO2023182342A1 - 骨格筋増強剤 - Google Patents
骨格筋増強剤 Download PDFInfo
- Publication number
- WO2023182342A1 WO2023182342A1 PCT/JP2023/011182 JP2023011182W WO2023182342A1 WO 2023182342 A1 WO2023182342 A1 WO 2023182342A1 JP 2023011182 W JP2023011182 W JP 2023011182W WO 2023182342 A1 WO2023182342 A1 WO 2023182342A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle
- skeletal muscle
- skeletal
- atrophy
- spd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Definitions
- the present invention relates to a skeletal muscle strengthening agent containing spermidine or a pharmaceutically acceptable salt thereof, which is characterized by being administered intramuscularly.
- Non-Patent Document 1 Skeletal muscle homeostasis is controlled by a synthesis system and a decomposition system (Non-Patent Document 1). When maintenance of this homeostasis breaks down and the degradative system becomes dominant, a decrease in skeletal muscle mass (hereinafter also referred to as "muscle atrophy") occurs. Age, immobility, neurodegenerative diseases, cachexia (malnutrition caused by cancer, etc.) are known causes of muscle atrophy. Muscle atrophy, which is caused by aging and frequently occurs in elderly people, is also called sarcopenia (Non-Patent Document 2). When sarcopenia develops and muscle atrophy progresses throughout the body, daily life activities decline and require nursing care and support, which is a major problem in an aging society.
- Non-Patent Document 11 Muscle atrophy caused by immobility is also called disuse muscle atrophy. Disuse muscle atrophy occurs due to immobilization in casts when treating fractures caused by injury or osteoporosis, or long-term bedriddenness due to old age. Exercise therapy that increases skeletal muscle mass is effective for muscle atrophy, but there is a desire to develop treatments (drug therapy, etc.) that can be applied to people who have difficulty exercising. As a mechanism of muscle atrophy, activation of muscle-specific ubiquitin/proteasome system and involvement of myogenesis inhibitory factors are known (Non-Patent Document 1).
- Tirm63 (MuRF1) is a typical muscle-specific ubiquitin ligase involved in muscle atrophy, and it has been reported that suppressing its expression suppresses muscle atrophy (Non-Patent Document 3).
- Myostatin (Mstn) is a myogenesis inhibitory factor, and it has been reported that suppressing its expression significantly increases muscle mass (Non-Patent Document 4).
- Muscle damage is a decrease in skeletal muscle mass that occurs due to a cause other than the breakdown of homeostasis. Muscle injuries are clinically classified into those caused by muscle strains, high-energy trauma, surgical operations, and the like. Muscle damage is known to cause various complications (dysfunction, muscle atrophy, local pain, etc.) (Non-Patent Document 9). Among muscle injuries, muscle contusions caused by blunt external force (contusions) are the most frequent sports injuries (Non-Patent Document 10). Although there are no accurate statistics, the number of patients in Japan is thought to be in the tens of thousands annually.
- Hepatocyte growth factor (Non-patent document 7) and insulin-like growth factor 1 (IGF-1) (Non-patent document 8) are known as factors that promote muscle regeneration. Furthermore, it has been reported that muscle hypertrophy can be induced by suppressing factors that inhibit muscle regeneration (Patent Document 1). However, muscle regeneration by the above mechanism requires a long time. Therefore, conventional treatment methods that do not take special measures to promote muscle regeneration cause muscle weakness, which delays muscle injury patients' return to daily life or sports activities. Furthermore, if muscle regeneration takes time, part of the muscle tissue may be replaced by scar tissue derived from collagen that remains in the muscle tissue for a long period of time.
- Non-Patent Document 9 Muscle regeneration is known to be promoted when skeletal muscle homeostasis becomes synthetic-based and muscle fibers are formed (Non-patent Documents 5 and 6).
- the present inventor found that intramuscular administration of spermidine to subjects suffering from muscle atrophy or muscle damage suppresses the decomposition system or inhibits the synthesis system in skeletal muscle homeostasis. It was discovered that the weight of skeletal muscles increases (that is, skeletal muscle reinforcement) as a result of this, and this led to the completion of the present invention. That is, the present invention relates to the following [1] to [10].
- the skeletal muscle strengthening agent according to [1] above which is administered to a subject with skeletal muscle atrophy.
- the skeletal muscle strengthening agent according to [4] above, wherein the skeletal muscle damage is due to a myogenic disease.
- the skeletal muscle strengthening agent of the present invention can strengthen skeletal muscle.
- Figure 1 shows the effect of intramuscular administration of spermidine trihydrochloride (SPD) on skeletal muscle weight in a muscle atrophy model.
- Figure 2 shows the effect of intramuscular administration of SPD on muscle fiber area in a muscle atrophy model.
- Figure 3 shows the effect of SPD administration to a muscle atrophy model on Trim63 gene expression.
- Figure 4 shows the effect of SPD administration to a muscle atrophy model on Mstn gene expression.
- Figure 5 shows the effect on skeletal muscle weight of SPD administration to a muscle injury model.
- Figure 6 shows the effect of intramuscular administration of SPD on the regenerated muscle area in a muscle injury model.
- Figure 7 shows the effect of intraperitoneal administration of SPD on the regenerated muscle area to a muscle injury model.
- FIG. 8 shows the effect of oral administration of SPD to a muscle injury model on regenerated muscle area.
- the skeletal muscle enhancing agent of the present invention contains spermidine or a pharmaceutically acceptable salt thereof as an active ingredient.
- Spermidine H 2 N(CH 2 ) 4 NH(CH 2 ) 3 NH 2
- Pharmaceutically acceptable salts of spermidine include hydrochloride, phosphate, and the like.
- Spermidine salts also include solvates with pharmaceutically acceptable solvents such as water or ethanol.
- Spermidine and its salts are known substances and are easily available on the market or can be easily produced by known means.
- “Skeletal muscle enhancer” refers to increasing the amount of skeletal muscle that has decreased due to muscle atrophy, muscle damage, etc.
- the increase in skeletal muscle mass is due to the suppression of the degradative system or the promotion of the synthetic system during skeletal muscle homeostasis, whereby the synthetic system dominates ( This is thought to be achieved by increasing the number of single muscle fibers that make up skeletal muscle and/or hypertrophying the single muscle fibers themselves.
- Muscle atrophy refers to a decrease in skeletal muscle mass that occurs when the degradative system becomes predominant among the synthetic and degradative systems that maintain skeletal muscle homeostasis.
- causes of muscle atrophy include aging, immobility, neurodegenerative diseases (amyotrophic lateral sclerosis, spinal muscular atrophy, etc.), cachexia, and the like.
- Muscle damage refers to a decrease in skeletal muscle mass that occurs due to causes other than disruption of homeostasis (such as necrosis of muscle fibers due to external forces or myogenic diseases).
- Muscle injuries caused by external forces include, for example, muscle strains (caused by external forces (such as bruises)), muscle strains (caused by internal forces such as rapid muscle contraction), and cervical sprains. (so-called whiplash), etc.
- Examples of myogenic diseases that cause muscle damage include muscular dystrophy and distal myopathy. Note that muscle damage caused by external forces and muscle damage caused by myogenic diseases have in common that compensatory muscle regeneration occurs in response to necrosis of muscle fibers (muscle damage).
- Skeletal muscle-enhancing agents used in drug therapy can be used to treat subjects for whom exercise therapy is difficult, especially muscle atrophy due to aging (sarcopenia), muscle atrophy due to disuse muscle atrophy, and muscle damage caused by external forces (especially muscle strains). It is suitable for treating subjects with muscle damage caused by myogenic diseases.
- the concentration of spermidine or its salt as a skeletal muscle enhancer can be appropriately set depending on the degree of muscle atrophy or muscle damage.
- Skeletal muscle enhancing agents can be applied to animals with skeletal muscles without restriction.
- the subject of application is preferably a mammal (human and non-human mammal (eg, horse or cow)), more preferably a human.
- the applicable gender and age do not matter.
- Skeletal muscle enhancing agents are administered intramuscularly to skeletal muscle. Intramuscular administration is more effective than other routes of administration. Preparations for intramuscular administration include, for example, sterilized liquid preparations such as solutions or suspensions, and specifically injections. For formulation, common formulation techniques can be used.
- Formulations for intramuscular administration may contain, in addition to the active ingredient, a pharmaceutically acceptable solvent or diluent.
- pharmaceutically acceptable solvents or diluents include distilled water for injection, lidocaine hydrochloride aqueous solution (for intramuscular injection), physiological saline, glucose aqueous solution, ethanol, polyethylene glycol, propylene glycol, and for intravenous injection.
- liquids for example, aqueous solutions of citric acid and sodium citrate
- electrolyte solutions for intravenous drip and intravenous injection
- Injections can be in the form of pre-dissolved active ingredients, or in the form of powdered active ingredients or those with an appropriate carrier added and dissolved before use. The injection can contain, for example, 0.005 to 25% by weight of the active ingredient based on the weight of the entire preparation.
- the skeletal muscle enhancing agent of the present invention can also be understood as a therapeutic agent for skeletal muscle atrophy or damage.
- the active ingredients and formulation of the therapeutic agent the explanations given for the skeletal muscle enhancing agent apply.
- the skeletal muscle enhancing agent of the present invention can also be understood as a skeletal muscle homeostasis restoring agent.
- the active ingredients and formulation of the recovery agent the explanations given for the skeletal muscle enhancer apply.
- Muscle atrophy model An animal model was used in which muscle atrophy was caused by a method of immobilizing the hind limbs (J Appl Physiol, vol.106, pp.2049-2059, 2009). Under isoflurane anesthesia, the left hind limb of the mouse in a flexed state was fixed using a surgical stapler (Kaiser Plus, Keisei Medical Industries, Ltd.). The right hindlimb of the same mouse was treated as the sham-treated side, and no immobilization treatment was performed. Three or seven days after the start of fixation, the tibialis anterior muscle (one of the skeletal muscles) was harvested by dissection. Samples collected after 3 days were used for expression analysis of muscle atrophy-related genes, and samples collected after 7 days were used for measurement of muscle weight and preparation of muscle tissue sections.
- the synthesized cDNA was subjected to real-time PCR method (using Applied Biosystems 7500 real-time PCR system (Thermo Fisher Scientific)) to measure the mRNA expression of three genes Trim63 (MuRF1), myostatin (Mstn), and Gapdh. .
- the primer sequences used are as follows. Tirm63 (MuRF1) has been reported to suppress muscle atrophy by inhibiting its expression (Non-Patent Document 3), and is a gene that acts to enhance the degradative system in skeletal muscle homeostasis.
- Myostatin has been reported to be a myogenesis inhibitory factor (Non-Patent Document 4), and is a gene that acts to suppress the synthetic system (in other words, enhance the degradative system) in skeletal muscle homeostasis.
- Gapdh was used as a control to standardize the expression levels of muscle atrophy-related genes.
- the expression levels of Trim63 and Mstn mRNA (mTrim63 and mMstn) were calculated as the ratio to the expression level of Gapdh mRNA (mGapdh). Evaluation was performed based on the ratio (%) of the expression level in other administration groups when the expression level in the fixed left hindlimb of the Vehicle administration group (details will be described later) was taken as 100%.
- Muscle damage model We used a model animal in which muscle damage was caused by administration of snake venom cardiotoxin (CTX). This model animal is widely used in research on muscle regeneration from injury. Under isoflurane anesthesia, 50 ⁇ L of 10 ⁇ M CTX was administered to the tibialis anterior muscle of the right hind leg of the mouse. 50 ⁇ L of phosphate buffered saline (PBS) was administered as a vehicle to the tibialis anterior muscle of the left hind leg of the same mouse. Seven days after CTX administration, the tibialis anterior muscle was collected by dissection and used for measurement of muscle weight and preparation of muscle tissue sections.
- CTX snake venom cardiotoxin
- Laminin which the primary antibody binds to, is a protein expressed in the basement membrane of all myocytes, so in this experiment it was used as an index to measure the area of individual myocytes in the section.
- the muscle tissue sections were washed with PBS, and then reacted with the secondary antibody (CF 488A Goat Anti-Rat IgG(H+L) (Biotium)) diluted 500 times with a blocking reagent for 1 hour. I let it happen.
- the secondary antibody which is an anti-rat antibody conjugated with a fluorescent dye, binds to the primary antibody and stains laminin.
- the muscle tissue sections were washed with PBS, mounted using "VECTASHIELD Hard Set with DAPI" (Vector), and subjected to fluorescence observation using an inverted microscope FSX100 (Olympus).
- the muscle fiber cross-sectional area was measured based on image data obtained by fluorescence observation. After importing the image data into the image analysis software ImageJ (NIH), the cross-sectional area of individual cells was measured based on the laminin-stained cell basement membrane. “Analyze Particles”, an analysis program built into ImageJ, was used for area measurement. The measurement results were expressed as a distribution diagram (histogram) of the area and number of single muscle fibers, and an average value of the cross-sectional area of all single muscle fibers (average muscle fiber area). In the muscle damage model (Example 3), regenerated muscles were measured.
- a central nuclear fiber (single muscle fiber with a central nucleus) that has a nucleus stained with DAPI contained in the mounting medium in the center of the cell is determined to be a regenerated muscle, and a muscle that existed before regeneration (the central nucleus) is determined to be a regenerated muscle. (not having a nucleus).
- the entire muscle was measured without distinction based on the central nucleus.
- Example 1 Spermidine trihydrochloride (SPD) was administered intramuscularly to muscle atrophy model animals, and changes in skeletal muscle weight and cross-sectional area of skeletal muscle fibers were evaluated.
- SPD serum trihydrochloride
- a preparation prepared by dissolving SPD in PBS SPD concentration: 196 mM
- This preparation (volume: 10 ⁇ L) was administered by injection into the tibialis anterior muscle of both legs of the model once a day from the day before left hind limb immobilization until the day before dissection.
- PBS Vehicle
- the intramuscularly administered group showed significant inhibition of muscle weight loss due to hindlimb immobilization (Figure 1, **P ⁇ 0.01).
- the histogram of the SPD intramuscular administration group shifted to the right (in the direction of increasing area) compared to the histogram of the vehicle administration group, and a significant increase in the average muscle fiber area was observed.
- Figure 2, ***P ⁇ 0.001 These results indicate that intramuscular administration of SPD inhibits the degradative system in skeletal muscle homeostasis or promotes the synthetic system (skeletal muscle) in subjects with normal skeletal muscle and subjects with disuse muscle atrophy. This shows that the muscles have been strengthened.
- SPD Spermidine trihydrochloride
- This preparation (volume: 10 mL/kg) was administered by intraperitoneal injection to the model once a day from the day before left hind limb immobilization until the day before dissection.
- a preparation prepared by dissolving SPD in water (SPD concentration: 30 mM) was used. This preparation was orally administered through ad libitum drinking water from the day before left hindlimb immobilization until immediately before dissection. The average amount of water consumed during the oral administration period was 2.26 mL/day per mouse.
- PBS vehicle
- SPD Spermidine trihydrochloride
- This preparation (volume: 10 mL/kg) was administered by intraperitoneal injection to the model once a day from the day before CTX administration until the day before dissection.
- a preparation prepared by dissolving SPD in water (SPD concentration: 30 mM) was used. This preparation was orally administered through free drinking water from the day before CTX administration until just before autopsy. The average amount of water consumed during the oral administration period was 2.32 mL/day per mouse.
- PBS vehicle
- water was used as a control in the oral administration group.
- the present invention can be used to treat muscle atrophy and muscle damage.
- SEQ ID NO: 1 Primer for sense strand of Trim63
- SEQ ID NO: 2 Primer for antisense strand of Trim63
- SEQ ID NO: 3 Primer for sense strand of Mstn
- SEQ ID NO: 4 Primer for antisense strand of Mstn
- SEQ ID NO: 5 Sense strand of Gapdh primer sequence number 6: Primer for antisense strand of Gapdh
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23774937.9A EP4497435A4 (en) | 2022-03-22 | 2023-03-22 | SKELETAL MUSCLE STRENGTHENING AGENT |
| US18/849,050 US20250228796A1 (en) | 2022-03-22 | 2023-03-22 | Skeletal muscle enhancer |
| JP2024509154A JPWO2023182342A1 (cg-RX-API-DMAC7.html) | 2022-03-22 | 2023-03-22 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022045904 | 2022-03-22 | ||
| JP2022-045904 | 2022-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023182342A1 true WO2023182342A1 (ja) | 2023-09-28 |
Family
ID=88101118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/011182 Ceased WO2023182342A1 (ja) | 2022-03-22 | 2023-03-22 | 骨格筋増強剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250228796A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4497435A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023182342A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023182342A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025070707A1 (ja) * | 2023-09-29 | 2025-04-03 | 東洋紡株式会社 | フレイルを予防、又は改善するためのジアミン、及び/又はポリアミンを含む組成物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5998015A (ja) * | 1982-11-27 | 1984-06-06 | Microbial Chem Res Found | 免疫賦活剤 |
| JP2002510618A (ja) * | 1998-04-03 | 2002-04-09 | イレンチャック,セオドア,トニー | 皮膚科症状の治療へのポリアミンの使用 |
| WO2013039244A1 (ja) | 2011-09-15 | 2013-03-21 | 生化学工業株式会社 | 骨格筋再生促進剤 |
| JP2021506230A (ja) * | 2017-12-20 | 2021-02-22 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法 |
| WO2021200216A1 (ja) * | 2020-04-03 | 2021-10-07 | 三菱瓦斯化学株式会社 | 筋肉増強剤 |
-
2023
- 2023-03-22 US US18/849,050 patent/US20250228796A1/en active Pending
- 2023-03-22 EP EP23774937.9A patent/EP4497435A4/en active Pending
- 2023-03-22 WO PCT/JP2023/011182 patent/WO2023182342A1/ja not_active Ceased
- 2023-03-22 JP JP2024509154A patent/JPWO2023182342A1/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5998015A (ja) * | 1982-11-27 | 1984-06-06 | Microbial Chem Res Found | 免疫賦活剤 |
| JP2002510618A (ja) * | 1998-04-03 | 2002-04-09 | イレンチャック,セオドア,トニー | 皮膚科症状の治療へのポリアミンの使用 |
| WO2013039244A1 (ja) | 2011-09-15 | 2013-03-21 | 生化学工業株式会社 | 骨格筋再生促進剤 |
| JP2021506230A (ja) * | 2017-12-20 | 2021-02-22 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法 |
| WO2021200216A1 (ja) * | 2020-04-03 | 2021-10-07 | 三菱瓦斯化学株式会社 | 筋肉増強剤 |
Non-Patent Citations (15)
| Title |
|---|
| AM. J. SPORTS MED., vol. 27, no. 1, 1999, pages 2 - 9 |
| AM. J. SPORTS MED., vol. 33, no. 5, May 2005 (2005-05-01), pages 745 - 64 |
| CELL. MOL. LIFE SCI., vol. 71, no. 22, 2014, pages 4361 - 4371 |
| CHRISAM MARTINA, PIROZZI MARINELLA, CASTAGNARO SILVIA, BLAAUW BERT, POLISHCHUCK ROMAN, CECCONI FRANCESCO, GRUMATI PAOLO, BONALDO P: "Reactivation of autophagy by spermidine ameliorates the myopathic defects of collagen VI-null mice", AUTOPHAGY, LANDES BIOSCIENCE, US, vol. 11, no. 12, 1 December 2015 (2015-12-01), US , pages 2142 - 2152, XP093095823, ISSN: 1554-8627, DOI: 10.1080/15548627.2015.1108508 * |
| DEV. BIOL., vol. 194, no. 1, 1998, pages 114 - 128 |
| FAN JINGJING, XIAOQI YANG, JIE LI, ZIYANG SHU, JUN DAI, XINGRAN LIU, BIAO LI, SHAOHUI JIA, XIANJUAN KOU, YI YANG, NING CHEN : "Spermidine coupled with exercise rescues skeletal muscle atrophy from D-gal- induced aging rats through enhanced autophagy and reduced apoptosis via AMPK-FOX03a signal pathway", ONCOTARGET, IMPACT JOURNALS LLC, UNITED STATES, vol. 8, no. 11, 14 March 2017 (2017-03-14), United States , pages 17475 - 17490, XP093095822, ISSN: 1949-2553, DOI: 10.18632/oncotarget.15728 * |
| J APPL PHYSIOL, vol. 106, 2009, pages 2049 - 2059 |
| J. APPL. PHYSIOL., vol. 95, no. 2, 2003, pages 771 - 780 |
| J. BONE JOINT SURG. AM., vol. 84, no. 5, May 2002 (2002-05-01), pages 822 - 32 |
| J. CELL. PHYSIOL., vol. 138, no. 2, 5 February 1989 (1989-02-05), pages 311 - 5 |
| PHYSIOLOGY, vol. 23, no. 3, 2008, pages 160 - 170 |
| SARCOPENIA MUSCLE, vol. 10, no. 5, 2019, pages 956 - 961 |
| SCIENCE, vol. 294, no. 5547, 2001, pages 1704 - 1708 |
| See also references of EP4497435A4 |
| SPINE & SPINAL CORD., vol. 30, no. 5, 2017, pages 573 - 578 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025070707A1 (ja) * | 2023-09-29 | 2025-04-03 | 東洋紡株式会社 | フレイルを予防、又は改善するためのジアミン、及び/又はポリアミンを含む組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4497435A4 (en) | 2025-08-13 |
| EP4497435A1 (en) | 2025-01-29 |
| JPWO2023182342A1 (cg-RX-API-DMAC7.html) | 2023-09-28 |
| US20250228796A1 (en) | 2025-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6823167B2 (ja) | ミオスタチン阻害剤の使用および併用療法 | |
| AU729463B2 (en) | Treatment of cardiomyopathy | |
| JP2005526107A (ja) | 慢性拒絶反応を予防および/または処置するための医薬 | |
| JP5340941B2 (ja) | 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用 | |
| CZ30474U1 (cs) | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření | |
| JP2010504083A5 (cg-RX-API-DMAC7.html) | ||
| WO2019069070A1 (en) | NEW SENOLYTIC PEPTIDES | |
| Goldspink et al. | Growth factors, muscle function and doping | |
| US20250228796A1 (en) | Skeletal muscle enhancer | |
| EP3870180B1 (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
| US20200031873A1 (en) | Repurposing cell penetrating peptides and their novel derivatives and iopromide and iodo-aryl carbonates for treatment of senescence-related diseases and disorders | |
| WO2020201444A1 (en) | Repurposing small molecules for senescence-related diseases and disorders | |
| EP1107778A1 (en) | Treatment of disease states | |
| US20130102662A1 (en) | Use of inducible nitric oxide synthase inhibitors and nitric oxide scavengers to inhibit post-traumatic immunodepression | |
| CN112587662A (zh) | 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用 | |
| WO2025208818A1 (zh) | 治疗下肢外周动脉疾病的核酸分子、药物组合物及其应用 | |
| EP4522191A1 (en) | Agents inducing vascularisation | |
| HK40060509A (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
| HK40060509B (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
| Hinkle et al. | Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals | |
| JP2024504085A (ja) | 筋ジストロフィーを治療するための方法および組成物 | |
| HK40043422A (en) | Use of myostatin inhibitors and combination therapies | |
| WO2026040961A1 (zh) | pUDK-HGF注射液的用途 | |
| HK40060507B (en) | Use of composition for preventing, ameliorating, or treating bone loss disorders, comprising cyclo-hispro (chp) and parathyroid hormone | |
| WO2018162722A1 (en) | Dpp-4 inhibitors for use in treating bone fractures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23774937 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2024509154 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18849050 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023774937 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023774937 Country of ref document: EP Effective date: 20241022 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18849050 Country of ref document: US |